BioSpace News Archive

The meeting takes place in Mumbai, India, February 7-10, 2018.

Laboratorio Noy (Lab Noy) announced today the launch of Oncocyst PD-L1, an assay using IncellDx technology that quantifies the percentage of abnormal bladder cells and immune cells from urine cytology specimens that express the immune-oncology marker PD-L1 using multi-parameter flow cytometry including cell cycle.

Anpac and its internationally-acclaimed medical research partners, are celebrating “National Cancer Prevention Day” by confirming a new, global milestone.

The trial is being conducted by the renowned Memorial Sloan Kettering Cancer Center (MSK) and led by MSK’s Dr. Alexander Shoushtari.

The primary endpoint of the trial is to determine the dose-limiting toxicity and recommended phase 2 doses of the doublet and triplet combinations.

Revenue reached DKK 17,234 million in 2017 representing an increase of 10% (12% in local currencies) compared to 2016 .

Therapix announced today that it has held a pre-Investigational New Drug communication with the FDA to discuss the regulatory pathway for the development of THX-110 for the treatment of Tourette Syndrome.

Attached as an exhibit to the Going-Private Statement is a preliminary proxy statement.

The grant of the status means that Galmed R&D will be subject to a reduced Israeli corporate tax rate that will range between 6%-12% on any future taxable “technological income” which includes sales, licenses and royalties from its IP protected products.

INP104 is a novel dihydroergotamine product dosed via Impel’s proprietary Precision Olfactory Delivery, or POD, intranasal delivery device.